Figure 5
MiR-29a/b expression post cisplatin treatment and their effects on NSCLC cells cisplatin resistance. (A) and (C) Relative expression of miR-29a and miR-29b in SPC-A-1 and A549 cells post cisplatin treatment for 0, 12, 24 and 36 h. The expression of miR-29a or miR-29b in “control” group at 0 h was set as “100%” in SPC-A-1 cell (A) or A549 cell (C). (B) and (D) Effects of miR-29a and miR-29b overexpression on SPC-A-1 and A549 cell viability upon cisplatin treatment. To detect the relationship between miR-29a/b expression and NSCLC cell cisplatin resistance, 0, 5, 10, 15, or 20 µg/ml cisplatin was used to treat SPC-A-1 or A549 cells for 12 hours.
